Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma

The efficacy of salvage treatment of diffuse large B‐cell lymphoma (DLBCL) patients who relapse or progress (rrDLBCL) after initial therapy is limited. Efficacy and safety of ofatumumab with iphosphamide, etoposide and cytarabine (O‐IVAC) was evaluated in a single‐arm study. Dosing was modified for...

Descripción completa

Detalles Bibliográficos
Autores principales: Paszkiewicz‐Kozik, Ewa, Michalski, Wojciech, Taszner, Michał, Mordak‐Domagała, Monika, Romejko‐Jarosińska, Joanna, Knopińska‐Posłuszny, Wanda, Najda, Jacek, Borawska, Anna, Chełstowska, Monika, Świerkowska, Monika, Dąbrowska‐Iwanicka, Anna, Malenda, Agata, Druzd‐Sitek, Agnieszka, Konecki, Robert, Kumiega, Beata, Osowiecki, Michał, Ostrowska, Beata, Szpila, Tomasz, Szymański, Marcin, Targoński, Łukasz, Domańska‐Czyż, Katarzyna, Popławska, Lidia, Giebel, Sebastian, Lange, Andrzej, Pluta, Andrzej, Zaucha, Jan Maciej, Rymkiewicz, Grzegorz, Walewski, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematological Malignancy‐clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322457/
https://www.ncbi.nlm.nih.gov/pubmed/35362096
http://dx.doi.org/10.1111/bjh.18166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322457/
https://www.ncbi.nlm.nih.gov/pubmed/35362096
http://dx.doi.org/10.1111/bjh.18166

Ejemplares similares